Abstract
Introduction
The impact of multiple primary tumors, in the setting of malignant glioma (MG), has not been heavily explored.
Methods
We extracted demographics and clinical data from the SEER-18 registry for adult patients with MGs. The cases were separated based on the sequence of MG diagnosis relative to the other primary tumors: Group (A) One primary only or first primary of multiple primaries and Group (B) second primary or subsequent primary tumor. Incidences, frequencies, and glioma-related survivals were analyzed.
Results
Group B constituted 12.8% of new MG. The incidences of group B, relative to those of all new MG, range from 0.14 to 0.18. Compared to group A, group B exhibited an older age. Moreover, group B exhibited a higher proportion of females, Caucasians, smaller tumors, non-operative cases, and those receiving radiation (p < 0.05); the proportion with GTR remained comparable. Multiple groupings (oral cavity, digestive system, respiratory system, skin, breast, genital systems, urinary system, lymphoma) exhibited lower glioma-related observed survival (p < 0.05) compared to Group A. An active diagnosis of “leukemia” appears to confer longer glioma-related survival while a history of “breast” or “digestive system” malignancies portends a shorter glioma-related survival.
Conclusion
For newly diagnosed MG, a high proportion does have history of extra-CNS primary tumors. Generally, these patients appear to have worse glioma-related observed survival compare to those with malignant glioma as the only primary or the first of multiple primary tumors. Knowledge regarding epidemiology, clinical factors, and observed survival can help guide clinical management/consultation for this subset of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Leading Causes of Death (2018) In: National Center for Health Statistics, vol 2018
Cancer Statistics (2018) In: National Cancer Institute, vol 2018
Frodin JE, Ericsson J, Barlow L (1997) Multiple primary malignant tumors in a national cancer registry–reliability of reporting. Acta Oncol 36:465–469
Moertel CG (1964) Incidence and significance of multiple primary malignant neoplasms. Ann NY Acad Sci 114:886–895
Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK (2016) Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 126:527–533
Boukerroucha M, Josse C, Segers K, El-Guendi S, Freres P, Jerusalem G et al (2015) BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer 15:181
Freedman RA, Wirth LJ, Chirieac LR, Huang EC (2007) Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol 25:2848–2850
Hayashi K, Ohtsuki Y, Sonobe H, Takahashi K, Wada S, Yoshida K (1987) An autopsy case of triple primary cancers consisting of glioblastoma multiforme of the pons, colon cancer and rectal carcinoid—a statistical analysis of cases of brain tumor combined with other primary cancers in Japan autopsy annuals. Gan No Rinsho 33:1846–1853
Raufi A, Alsharedi M, Khelfa Y, Tirona M (2017) Bilateral triple-negative invasive breast cancer with a BRCA2 mutation, and glioblastoma: a case report and literature review. J Breast Cancer 20:108–111
Epidemiology S, Results E (SEER) Program: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases. In: National Cancer Institute Division. Surveillance Research Program, Surveillance Systems Branch
Lin Y, Jea A, Melkonian SC, Lam S (2015) Treatment of pediatric Grade II spinal ependymomas: a population-based study. J Neurosurg Pediatr 15:243–249
Nguyen HS, Doan N, Gelsomino M, Shabani S (2017) Dysembryoplastic neuroectodermal tumor: an analysis from the surveillance, epidemiology, and end results program, 2004–2013. World Neurosurg 103:380–385
Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850
Nguyen HS, Shabani S, Awad AJ, Kaushal M, Doan N (2018) Molecular markers of therapy-resistant glioblastoma and potential strategy to combat resistance. Int J Mol Sci 19:1765
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS et al (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev 23:1985–1996
Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH et al (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 121:1115–1123
Baker P (2016) Men’s health: an overlooked inequality. Br J Nurs 25:1054–1057
Bates JE, Choi G, Milano MT (2016) Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. J Neurooncol 129:251–258
Kutsenko A, Berrington de Gonzalez A, Curtis RE, Rajaraman P (2014) Risk of second benign brain tumors among cancer survivors in the surveillance, epidemiology, and end results program. Cancer Causes Control 25:659–668
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Nguyen, H.S., Doan, N.B., Gelsomino, M. et al. Management and survival trends for adult patients with malignant gliomas in the setting of multiple primary tumors: a population based analysis. J Neurooncol 141, 213–221 (2019). https://doi.org/10.1007/s11060-018-03028-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-018-03028-4